Treatment for emphysema
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that treatments for emphysema include endobronchial valves, endobronchial coils, thermal vapour ablation, ATRA, and lung-volume-reduction surgery, all of which can improve lung function, exercise capacity, and quality of life.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Treatment Options for Emphysema: A Comprehensive Overview
Introduction to Emphysema Treatment
Emphysema, a chronic lung condition characterized by the destruction of alveoli, leads to severe respiratory issues. Various treatment options, ranging from medical management to surgical interventions, have been explored to improve the quality of life and lung function in patients with severe emphysema.
Spiration Valve System (SVS) for Severe Emphysema
The Spiration Valve System (SVS) is a less invasive, nonsurgical approach designed to treat severe heterogeneous emphysema. A multicenter, open-label, randomized controlled trial demonstrated that SVS significantly improved lung function, as measured by forced expiratory volume in one second (FEV1), and other secondary outcomes such as target lobe volume reduction, hyperinflation, health status, and dyspnea at 6 and 12 months. However, the treatment group experienced a higher incidence of serious adverse events, primarily pneumothorax.
Endobronchial Coils for Hyperinflation
Endobronchial coils (LVRCs) are another bronchoscopic treatment option for severe emphysema with hyperinflation. Clinical trials have shown that LVRCs can significantly improve quality of life, exercise capacity, and pulmonary function up to 12 months post-treatment . The treatment is generally well-tolerated, with a manageable safety profile, although some patients experienced serious adverse events such as COPD exacerbations and pneumonia .
Endobronchial Valves (EBVs) for Emphysema without Collateral Ventilation
Endobronchial valves (EBVs) are one-way valves used in bronchoscopic lung-volume reduction. Studies have shown that EBVs significantly improve pulmonary function, exercise capacity, and quality of life in patients with severe emphysema without interlobar collateral ventilation . However, the treatment is associated with a higher rate of serious adverse events, including pneumothorax and valve-related complications .
Thermal Vapour Ablation
Thermal vapour ablation is a targeted bronchoscopic treatment that selectively reduces the volume of more diseased segments of the lung. The STEP-UP trial demonstrated that this approach led to significant improvements in lung function and quality of life at 6 months, with an acceptable safety profile. The most common serious adverse event was COPD exacerbation, with one treatment-related death reported.
All-Trans-Retinoic Acid (ATRA)
All-trans-retinoic acid (ATRA) has been investigated for its potential to reverse emphysema. A pilot study found that ATRA was well-tolerated with mild side effects, but it did not result in significant improvements in pulmonary function or CT measurements. Further research is needed to explore higher doses or different dosing schedules.
Lung-Volume-Reduction Surgery (LVRS)
Lung-volume-reduction surgery (LVRS) has been a traditional treatment for severe emphysema. The National Emphysema Treatment Trial (NETT) showed that LVRS can improve exercise capacity and quality of life, particularly in patients with upper-lobe-predominant emphysema and low baseline exercise capacity . However, the surgery does not confer a survival advantage over medical therapy and is associated with higher mortality in certain subgroups .
Conclusion
The treatment landscape for severe emphysema includes a variety of options, each with its own benefits and risks. Bronchoscopic interventions such as SVS, LVRCs, and EBVs offer less invasive alternatives to surgery, with significant improvements in lung function and quality of life. However, these treatments come with a risk of serious adverse events. LVRS remains a viable option for specific patient subgroups, while ATRA requires further investigation. Personalized treatment plans should be developed based on individual patient characteristics and disease severity.
Sources and full results
Most relevant research papers on this topic
